Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD

4.41  -0.26 (-5.57%)

After market: 4.33 -0.08 (-1.81%)

Fundamental Rating

2

Overall EKSO gets a fundamental rating of 2 out of 10. We evaluated EKSO against 188 industry peers in the Health Care Equipment & Supplies industry. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative. EKSO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EKSO had negative earnings in the past year.
EKSO had a negative operating cash flow in the past year.
EKSO had negative earnings in each of the past 5 years.
EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.52%, EKSO is doing worse than 63.83% of the companies in the same industry.
The Return On Equity of EKSO (-85.03%) is worse than 60.11% of its industry peers.
Industry RankSector Rank
ROA -39.52%
ROE -85.03%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

EKSO's Gross Margin of 53.39% is in line compared to the rest of the industry. EKSO outperforms 46.81% of its industry peers.
In the last couple of years the Gross Margin of EKSO has grown nicely.
EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
EKSO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EKSO has been increased compared to 5 years ago.
Compared to 1 year ago, EKSO has an improved debt to assets ratio.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -7.55, we must say that EKSO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.55, EKSO is doing worse than 76.60% of the companies in the same industry.
EKSO has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
EKSO's Debt to Equity ratio of 0.28 is in line compared to the rest of the industry. EKSO outperforms 49.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -7.55
ROIC/WACCN/A
WACC8.83%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EKSO has a Current Ratio of 2.35. This indicates that EKSO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.35, EKSO is in line with its industry, outperforming 43.62% of the companies in the same industry.
EKSO has a Quick Ratio of 1.77. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.77, EKSO perfoms like the industry average, outperforming 47.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.77
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.48% over the past year.
EKSO shows a decrease in Revenue. In the last year, the revenue decreased by -2.06%.
EKSO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.19% yearly.
EPS 1Y (TTM)49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)-2.06%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-10.14%

3.2 Future

Based on estimates for the next years, EKSO will show a very strong growth in Earnings Per Share. The EPS will grow by 21.72% on average per year.
The Revenue is expected to grow by 18.01% on average over the next years. This is quite good.
EPS Next Y35.58%
EPS Next 2Y25.68%
EPS Next 3Y21.72%
EPS Next 5YN/A
Revenue Next Year-1.46%
Revenue Next 2Y18.41%
Revenue Next 3Y18.01%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EKSO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EKSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

EKSO's earnings are expected to grow with 21.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3Y21.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (6/3/2025, 8:00:02 PM)

After market: 4.33 -0.08 (-1.81%)

4.41

-0.26 (-5.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-28 2025-07-28/amc
Inst Owners19.35%
Inst Owner Change-4.97%
Ins Owners6.89%
Ins Owner Change5.66%
Market Cap128.07M
Analysts82.5
Price Target5.1 (15.65%)
Short Float %N/A
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.26%
Min EPS beat(2)-71.57%
Max EPS beat(2)-6.95%
EPS beat(4)2
Avg EPS beat(4)-17.48%
Min EPS beat(4)-71.57%
Max EPS beat(4)6.63%
EPS beat(8)3
Avg EPS beat(8)-21.63%
EPS beat(12)4
Avg EPS beat(12)-17.76%
EPS beat(16)8
Avg EPS beat(16)-7.67%
Revenue beat(2)0
Avg Revenue beat(2)-14.85%
Min Revenue beat(2)-28.45%
Max Revenue beat(2)-1.24%
Revenue beat(4)0
Avg Revenue beat(4)-15.73%
Min Revenue beat(4)-28.45%
Max Revenue beat(4)-1.24%
Revenue beat(8)2
Avg Revenue beat(8)-10.4%
Revenue beat(12)3
Avg Revenue beat(12)-5.17%
Revenue beat(16)6
Avg Revenue beat(16)-1.33%
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-63.64%
EPS NY rev (1m)-12.5%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)-21.73%
Revenue NQ rev (3m)-26.9%
Revenue NY rev (1m)-19.95%
Revenue NY rev (3m)-25.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.3
P/FCF N/A
P/OCF N/A
P/B 10.09
P/tB 16.12
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.6
BVpS0.44
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.52%
ROE -85.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.39%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.47%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.77
Altman-Z -7.55
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y35.58%
EPS Next 2Y25.68%
EPS Next 3Y21.72%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.06%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-10.14%
Revenue Next Year-1.46%
Revenue Next 2Y18.41%
Revenue Next 3Y18.01%
Revenue Next 5YN/A
EBIT growth 1Y24.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.19%
OCF growth 3YN/A
OCF growth 5YN/A